CompletedPhase 3NCT02634931
Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex
Studying Tuberous sclerosis complex
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nobelpharma
- Principal Investigator
- Mari Wataya-Kaneda,, MD, PhDDepartment of Dermatology, Graduate School of Medicine, Osaka University
- Intervention
- NPC-12G gel(drug)
- Enrollment
- 94 enrolled
- Eligibility
- 3 years · All sexes
- Timeline
- 2015 – 2018
Study locations (1)
- Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02634931 on ClinicalTrials.govOther trials for Tuberous sclerosis complex
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT06879665TANDem-2: Closing the Gap to Interventions for TANDVrije Universiteit Brussel
- RECRUITINGPHASE3NCT07403266Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)Oils4Cure
- RECRUITINGNANCT06160310Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)David M. Ritter
- RECRUITINGPHASE2NCT05104983Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention StudyDarcy Krueger
- RECRUITINGNANCT06764602Observational, Retrospective, Multicenter, Nonprofit Study on the Prevalence of Renal Involvement in Pediatric Patients With Tuberous SclerosisIRCCS Azienda Ospedaliero-Universitaria di Bologna
- ACTIVE NOT RECRUITINGNANCT04198181The Effectiveness and Safety of Resective Epilepsy Surgery for TREBeijing Children's Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentNovartis Pharmaceuticals
- RECRUITINGNANCT00001465Study of the Disease Process of LymphangioleiomyomatosisNational Heart, Lung, and Blood Institute (NHLBI)